Evidence map›Paper›PMID 40241574›Full record

ArticleHaematologica2025

Novel PROTAC to target FKBP12: the potential to enhance bone morphogenetic protein activity and apoptosis in multiple myeloma.

Ingrid Quist-Lokken, Mira Tilseth, Clara Andersson-Rusch, Md Abu Hanif, Michael Walz, Johanna Fredrikke Nordstrand Moen, Megan Anne Vik, Tobias Schmidt Slordahl, Anders Sundan, Felix Hausch and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Current Status of Molecularly Targeted Therapeutics in Blood Cancers.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ingrid Quist-LokkenDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim.
Mira TilsethDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway; Department of Hematology, St. Olav's University Hospital, Trondheim.
Clara Andersson-RuschDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway; Department of Hematology, St. Olav's University Hospital, Trondheim.
Md Abu HanifDepartment of Biomedical Laboratory Science, Norwegian University of Science and Technology - NTNU, Trondheim.
Michael WalzDepartment of Chemistry, Technical University of Darmstadt, Darmstadt.
Johanna Fredrikke Nordstrand MoenDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim.
Megan Anne VikDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim.
Tobias Schmidt SlordahlDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway; Department of Hematology, St. Olav's University Hospital, Trondheim.
Anders SundanDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway; Department of Hematology, St. Olav's University Hospital, Trondheim.
Felix HauschDepartment of Chemistry, Technical University of Darmstadt, Darmstadt, Germany; Centre for Synthetic Biology, Technical University of Darmstadt, Darmstadt.
Toril HolienDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology - NTNU, Trondheim, Norway; Department of Hematology, St. Olav's University Hospital, Trondheim, Norway; Department of Biomedical Laboratory Science, Norwegian University of Science and Technology - NTNU, Trondheim, Norway; Department of Immunology and Transfusion Medicine, St. Olav's University Hospital, Trondheim. toril.holien@ntnu.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40241574
PMCPMC12485307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.